a2 Milk (ASX:A2M) share price on watch after downgrading guidance again

The A2 Milk Company Ltd (ASX:A2M) share price will be on watch on Thursday after it downgraded its FY 2021 guidance was again…

The A2 Milk Company Ltd (ASX: A2M) share price will be one to watch on Thursday.

This follows the release of the fresh milk and infant formula company's half year results this morning.

white arrow pointing down

Image source: Getty Images

How did a2 Milk perform in the first half?

The good news for shareholders and the a2 Milk share price is that the company delivered a result in line with its downgraded guidance.

For the six months ended 31 December, the company reported a 16% decline in revenue to NZ$677.4 million. This compares to its guidance of ~NZ$670 million for the half.

In respect to earnings, a2 Milk posted a 32.2% decline in earnings before interest, tax, depreciation and amortisation (EBITDA) to NZ$178.5 million.

While this means that its EBITDA margin came in below its guidance of ~27%, this was due to Mataura Valley Milk acquisition costs. Excluding these costs, a2 Milk's EBITDA margin would have been in line at 27%.

And on the bottom line, the company's net profit after tax fell 35% over the prior corresponding period to NZ$120 million.

Finally, a2 Milk reported a NZ$9.2 million operating cash outflow for the period. This was due to an increase in inventory and a decrease in accounts payable. Nevertheless, the company finished the period with a massive NZ$774.6 million cash balance and no debt.

Why did sales and earnings decline?

There have been a number of factors weighing on the company's performance and ultimately the a2 Milk share price.

The main one is of course weakness in the daigou and cross-border e-commerce (CBEC) channels. They have been significantly impacted due to disruption resulting primarily from COVID-19 related issues.

And although the company's China label infant nutrition products grew sales by 45.2% to NZ$213.1 million and its Australian and US liquid milk businesses continue to growth, it wasn't enough to offset this.

Also weighing on its performance was weaker gross margins. This was primarily due to recognising a stock provision of NZ$23.3 million, higher cost of goods sold for China label infant nutrition, pricing pressures, and an adverse product mix shift. The latter has seen a higher proportion of liquid milk to infant nutrition sales.

Guidance downgraded again

Although a2 Milk delivered a first half result in line with its guidance, it looks likely to fall short of its full year guidance. This could be bad news for the a2 Milk share price on Thursday.

Management commented:

"The pace of recovery in the daigou/reseller channel and in the CBEC channel has been slower than previously anticipated and the Company now expects revenue to be at the lower end of the previous guidance range."

"A lower EBITDA margin range is now expected due to lower revenue, higher brand investment, longer daigou/reseller support, movements in foreign currency and adverse channel mix relative to what was anticipated in December."

In light of this, it is forecasting FY 2021 revenue of ~NZ$1.4 billion. This compares to its previous guidance range of NZ$1.4 billion to NZ$1.55 billion.

As for its earnings, management now expects an EBITDA margin of 24% to 26% (excluding acquisition costs). This compares to its previously downgraded guidance for an EBITDA margin of 26% to 29%.

It is also worth noting that this guidance assumes that actions it is taking to reactivate the daigou/reseller channel deliver a significant improvement in quarter-on-quarter growth in the fourth quarter.

The a2 Milk share price is down 31% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »